Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Weak
Website
N/ATelephone
64.3.479.5800
Address
87 St. David Street Centre for Innovation Dunedin, Otago 9016
Description
Pacific Edge Ltd. engages in the provision of discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. It operates in the Commercial and Research segments. The Commercial segment involves the sales, marketing, laboratory, and support to run the commercial businesses worldwide. The Research segment engages in the research and development of diagnostic and prognostic products for human cancer. The company was founded on February 27, 2001 and is headquartered in Dunedin, New Zealand.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.18
Trade Value (12mth)
AU$674.00
1 week
1.03%
1 month
20.99%
YTD
-27.41%
1 year
27.27%
All time high
1.61
EPS 3 yr Growth
38.30%
EBITDA Margin
-136.90%
Operating Cashflow
-$23m
Free Cash Flow Return
-58.40%
ROIC
-70.60%
Interest Coverage
-854.70
Quick Ratio
3.00
Shares on Issue (Fully Dilluted)
812m
HALO Sector
Healthcare
Next Company Report Date
27-May-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.13
Date | Announcements |
---|---|
17 July 25 |
Pacific Edge Opens $5.0 Million Share Purchase Plan
×
Pacific Edge Opens $5.0 Million Share Purchase Plan |
17 July 25 |
Notice of Annual Shareholders' Meeting
×
Notice of Annual Shareholders' Meeting |
17 July 25 |
Appendix 3B - Proposed Issue of Securities - SPP
×
Appendix 3B - Proposed Issue of Securities - SPP |
17 July 25 |
Proposed issue of securities - PEB
×
Proposed issue of securities - PEB |
17 July 25 |
Proposed issue of securities - PEB
×
Proposed issue of securities - PEB |
17 July 25 |
Cancel - Proposed issue of securities - PEB
×
Cancel - Proposed issue of securities - PEB |
16 July 25 |
Pacific Edge - Cleansing Notice
×
Pacific Edge - Cleansing Notice |
14 July 25 |
Q1 26 Cxbladder Demand Resilient Despite Coverage Loss
×
Q1 26 Cxbladder Demand Resilient Despite Coverage Loss |
30 June 25 |
Annual Report 2025
×
Annual Report 2025 |
16 June 25 |
Letter to Shareholders
×
Letter to Shareholders |
03 June 25 |
Pacific Edge Placement Upsized to NZ$16 Million
×
Pacific Edge Placement Upsized to NZ$16 Million |
30 May 25 |
Trading Halt
×
Trading Halt |
30 May 25 |
Proposed issue of securities - PEB
×
Proposed issue of securities - PEB |
30 May 25 |
Pacific Edge Launches NZ $20m Capital Raise
×
Pacific Edge Launches NZ $20m Capital Raise |
30 May 25 |
Pacific Edge Reports Resilient Performance in FY25
×
Pacific Edge Reports Resilient Performance in FY25 |
12 May 25 |
Pacific Edge FY25 Result to be Announced 30 May 2025
×
Pacific Edge FY25 Result to be Announced 30 May 2025 |
29 April 25 |
Triage Plus Set to Lift Pacific Edge's Economics
×
Triage Plus Set to Lift Pacific Edge's Economics |
29 April 25 |
Pause in Trading
×
Pause in Trading |
28 April 25 |
Medicare LCD Effective - Pacific Edge Seeks Recoverage
×
Medicare LCD Effective - Pacific Edge Seeks Recoverage |
24 April 25 |
US COURT LACKS JURISDICTION TO HEAR PACIFIC EDGE CLAIM
×
US COURT LACKS JURISDICTION TO HEAR PACIFIC EDGE CLAIM |
04 April 25 |
Q4 25 Cxbladder Volumes Rise and Key Metrics Improve
×
Q4 25 Cxbladder Volumes Rise and Key Metrics Improve |
28 February 25 |
Cxbladder Incorporated into AUA Clinical Guideline
×
Cxbladder Incorporated into AUA Clinical Guideline |
28 January 25 |
Ongoing Disclosure Notice
×
Ongoing Disclosure Notice |
28 January 25 |
Medicare LCD Effective Date Extended to 24 April 2025
×
Medicare LCD Effective Date Extended to 24 April 2025 |
22 January 25 |
Pacific Edge Release Quarterly Volumes for Q3 FY25
×
Pacific Edge Release Quarterly Volumes for Q3 FY25 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.